This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Bioss
product type :
antibody
product name :
CDK7 Polyclonal Antibody
catalog :
bs-0569R
quantity :
100 ul
price :
279 USD
clonality :
polyclonal
host :
rabbit
conjugate :
nonconjugated
reactivity :
human, mouse, rat
application :
western blot, immunocytochemistry, immunohistochemistry - paraffin section
product information
sku :
bs-0569R
name :
CDK7 Polyclonal Antibody
category :
Primary Antibody
conjugation :
Unconjugated
host :
Rabbit
target protein :
CDK7
modification :
Unmodified
clonality :
Polyclonal
isotype :
IgG
concentration :
1ug/ul
public immunogen range :
10-50/346
subcellular locations :
Cytoplasm, Nucleus
source :
KLH conjugated synthetic peptide derived from human CDK7
gene id link :
Entrez Gene: 1022
swiss prot :
P50613
swiss prot link :
Swiss Prot: P50613
applications :
WB, IHC-P, IF(IHC-P)
applications with dilutions :
WB(1:100-1000), IHC-P(1:100-500), IF(IHC-P)(1:50-200)
cross reactive species :
Human, Mouse, Rat
size :
100 ul
price :
279 USD
background :
Serine/threonine kinase involved in cell cycle control and in RNA polymerase II-mediated RNA transcription. Cyclin-dependent kinases (CDKs) are activated by the binding to a cyclin and mediate the progression through the cell cycle. Each different complex controls a specific transition between 2 subsequent phases in the cell cycle. Required for both activation and complex formation of CDK1/cyclin-B during G2-M transition, and for activation of CDK2/cyclins during G1-S transition (but not complex formation). CDK7 is the catalytic subunit of the CDK-activating kinase (CAK) complex. Phosphorylates SPT5/SUPT5H, SF1/NR5A1, POLR2A, p53/TP53, CDK1, CDK2, CDK4, CDK6 and CDK11B/CDK11. CAK activates the cyclin-associated kinases CDK1, CDK2, CDK4 and CDK6 by threonine phosphorylation, thus regulating cell cycle progression. CAK complexed to the core-TFIIH basal transcription factor activates RNA polymerase II by serine phosphorylation of the repetitive C-terminal domain (CTD) of its large subunit (POLR2A), allowing its escape from the promoter and elongation of the transcripts. Phosphorylation of POLR2A in complex with DNA promotes transcription initiation by triggering dissociation from DNA. Its expression and activity are constant throughout the cell cycle. Upon DNA damage, triggers p53/TP53 activation by phosphorylation, but is inactivated in turn by p53/TP53; this feedback loop may lead to an arrest of the cell cycle and of the transcription, helping in cell recovery, or to apoptosis. Required for DNA-bound peptides-mediated transcription and cellular growth inhibition.
purification :
Purified by Protein A.
storage :
Aqueous buffered solution containing 1% BSA, 50% glycerol and 0.09% sodium azide. Store at -20°C for 12 months.
synonyms :
CAK1; HCAK; MO15; STK1; CDKN7; p39MO15; Cyclin-dependent kinase 7; 39 kDa protein kinase; p39 Mo15; CDK-activating kinase 1; Cell division protein kinase 7; Serine/threonine-protein kinase 1; TFIIH basal transcription factor complex kinase subunit; CDK7; CAK
lead time :
3 to 5 business days.
company information
Bioss
500 West Cummings Park
Suite 6500
Woburn, MA 01801
info@biossusa.com
http://biossusa.com
800-501-7654
headquarters: USA
Bioss Inc is a leading antibody developer and manufacturer with state of the art technologies. We have developed over 11,000 antigens/primary antibodies and more than 130,000 derived products including fluorochrome conjugated antibodies. In addition to reliable loading control and tag antibodies, our catalog includes over 1000 specific antibodies recognizing proteins with phosphorylation, acetylation, or methylation modifications. Our company promises fast delivery with strong, top quality scientific support. Bioss Inc is located in the greater Boston area of Massachusetts, the center of the world's largest and fastest growing biotech community.